Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

Prospects for an HIV Vaccine: Conventional Approaches and DNA Immunization

“…These findings may suggest that neutralizing antibodies to HIV represent a correlate for protection. Protection against S1V and HIV infection has been achieved in monkeys following passive transfer of antibodies from SIV and SHIV models to na ve monkeys, indirectly supporting this hypothesis (Rinaldo et al, 1995;Haigwood et al, 1996;Van Rompay et al, 1998;Mascola et al, 1999). In addition, adoptive transfer of NIH 3T3 cells transfected with a gene encoding a human monoclonal antibody (mAb), known to neutralize 1-IV-1, into a severe combined immunodeficiency (SCID) mouse model, reconstituted with HIV-infected human lymphocytes, has been recently shown to significantly reduce viral load in these mice (Sanhadji et al, 2000).…”

CD8 + Lymphocytes Do Not Mediate Protection against Acute Superinfection 20 Days after Vaccination with a Live Attenuated Simian Immunodeficiency Virus

“…An inverse correlation between neutralizing antibody titers and plasma virus levels in SIV-infected and B-cell depleted macaques has been reported (42). Similarly, postchallenge immunotherapy with purified immunoglobulin from SIV-infected long-term nonprogressors is reported to reduce virus burden (21). It could be argued that the more marked anti-SIVgp130 serological response contributed to protection against superinfection and impaired the ability to determine the mechanism of protection.…”

Dissecting the Humoral Immune Response to Simian Immunodeficiency Virus: Mechanisms of Antibody-Mediated Virus Neutralization

“…cytotoxic T lymphocytes (CTLs) in mediating viral control during the primary infection and in maintaining the viral set-point in chronic infection (3,4). While less is known about virusspecific antibody responses, passive protection experiments have demonstrated the protective efficacy of antibodies against virus exposure in the SIV/monkey (5)(6)(7)(8) and SHIV/ monkey models (9)(10)(11)(12)(13)(14)(15), demonstrating the ability of antibody alone to mediate sterile protection against pathogenic virus challenge. This review highlights the work in our lab to understand the quantitative and qualitative properties of antibody responses associated with the development of protective immunity in the SIV/macaque model for AIDS vaccine development, specifically focusing on defining the mechanism(s) by which antibody neutralizes SIV in vitro.…”